Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Off-Label Communication: When Does It Align With Approved Labeling?

Executive Summary

US FDA draft guidance offers three-factor test to determine when communication about a medical product is consistent with labeling; information on patient-reported outcomes and mechanism of action are okay.

You may also be interested in...



US FDA Tiptoes Further Into Off-Label Use Discussions With CURE ID App

App allows clinicians to discuss off-label treatments, but information is intended to be hypothesis-generating, not for regulatory use.

When Expanded Access Also Means Off-Label Use, US FDA May Need New Policy

For now, FDA is using a case-by-case approach for reviewing and approving expanded access applications asking for off-label uses.

Drug/Software Combos Likely Won't Require Pre-Market Review By US FDA

The agency explains that most drug-use-related apps will be considered promotional labeling, but sponsors should sometimes seek advisory comment. US FDA is seeking feedback from a variety of stakeholders on its discussion proposal for regulating prescription-drug-focused software.

Related Content

Topics

UsernamePublicRestriction

Register

PS119851

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel